Cleveland Clinic Health System - East Region
Cleveland Clinic Health System - East Region was paid $31.44M by Medicaid between Jan 2018 and Dec 2024, across 299 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
WARRENSVILLE HEIGHTS, OH 44122
Next to other General Acute Care Hospital providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 80,579 | $2.47M | |
| 2019 | 69,875 | $2.31M | |
| 2020 | 49,292 | $2.91M | |
| 2021 | 63,452 | $3.68M | |
| 2022 | 71,739 | $3.21M | |
| 2023 | 238,911 | $10.11M | |
| 2024incomplete | 192,046 | $6.73M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 36,476 | 34,054 | $4.86M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 33,781 | 30,977 | $4.85M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 31,105 | 27,112 | $4.78M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 10,292 | 6,977 | $3.42M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.6% | 24,501 | 18,914 | $2.08M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.8% | 8,436 | 7,168 | $1.19M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 3,233 | 2,665 | $974K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 4,350 | 3,924 | $722K |
| G0378 | Hospital observation service, per hour | 2.2% | 10,705 | 4,589 | $685K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 2,142 | 1,757 | $602K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,828 | 3,508 | $507K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 2,692 | 2,024 | $462K |
287 more codes
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 1,747 | $415K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 2,559 | $341K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,421 | $298K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,078 | $296K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 624 | $291K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,950 | $264K |
| 80053 | Comprehensive metabolic panel | <1% | 40,227 | $263K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,932 | $203K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,995 | $189K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 630 | $178K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 303 | $157K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 463 | $134K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 863 | $125K |
| 93970 | <1% | 658 | $91K | |
| 11045 | <1% | 156 | $86K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,218 | $72K |
| 71250 | <1% | 652 | $69K | |
| 97161 | <1% | 1,851 | $68K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 492 | $68K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 648 | $66K |
| 93971 | <1% | 651 | $64K | |
| 81513 | <1% | 388 | $63K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,434 | $62K |
| 82805 | <1% | 1,480 | $58K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 158 | $57K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 231 | $54K |
| 84484 | <1% | 15,933 | $51K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,902 | $51K |
| 93976 | <1% | 358 | $51K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 68,296 | $51K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,339 | $50K |
| 76830 | Ultrasound, transvaginal | <1% | 760 | $48K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,792 | $47K |
| 97165 | <1% | 871 | $46K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,488 | $46K |
| 80069 | <1% | 4,754 | $44K | |
| 85027 | <1% | 12,343 | $43K | |
| 76770 | <1% | 265 | $40K | |
| 87631 | <1% | 202 | $39K | |
| 93799 | <1% | 6,751 | $39K | |
| 97113 | <1% | 537 | $38K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,875 | $38K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 56 | $35K |
| 70498 | <1% | 85 | $35K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,141 | $33K |
| 80061 | Lipid panel | <1% | 2,495 | $31K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,161 | $30K |
| 43235 | <1% | 66 | $30K | |
| 83735 | <1% | 18,114 | $30K | |
| 86850 | <1% | 1,164 | $30K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 48 | $29K |
| 96367 | <1% | 707 | $29K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,768 | $28K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,534 | $27K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,321 | $27K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 960 | $26K |
| 74018 | <1% | 715 | $26K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,150 | $25K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,002 | $25K |
| 12001 | <1% | 118 | $24K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 257 | $24K |
| 97802 | <1% | 401 | $24K | |
| 73630 | <1% | 1,111 | $23K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,504 | $23K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 559 | $21K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 56 | $21K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 537 | $21K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,308 | $21K |
| 97116 | <1% | 720 | $20K | |
| 82962 | <1% | 13,523 | $20K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 926 | $19K |
| 73564 | <1% | 622 | $18K | |
| 86780 | <1% | 2,682 | $18K | |
| 99253 | <1% | 495 | $18K | |
| 70491 | <1% | 41 | $18K | |
| 70486 | <1% | 429 | $18K | |
| 73030 | <1% | 925 | $17K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 118 | $17K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 797 | $17K |
| 10060 | <1% | 79 | $16K | |
| 86900 | <1% | 1,189 | $16K | |
| 96127 | <1% | 468 | $16K | |
| 11043 | <1% | 96 | $16K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 731 | $15K |
| 81001 | <1% | 29,110 | $15K | |
| 82728 | <1% | 1,042 | $14K | |
| 73610 | <1% | 959 | $14K | |
| 86803 | <1% | 620 | $14K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 13 | $13K |
| 72100 | <1% | 575 | $13K | |
| 85610 | <1% | 11,573 | $13K | |
| 90715 | <1% | 738 | $13K | |
| 84702 | <1% | 1,025 | $13K | |
| 73130 | <1% | 888 | $12K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,223 | $12K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 369 | $11K |
| 82607 | <1% | 643 | $11K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 42 | $11K |
| 73560 | <1% | 799 | $11K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 1,262 | $10K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 86 | $10K |
| 86140 | <1% | 1,260 | $10K | |
| 83880 | <1% | 1,921 | $10K | |
| 72197 | <1% | 31 | $10K | |
| 99152 | <1% | 366 | $10K | |
| 83540 | <1% | 1,119 | $10K | |
| 84439 | <1% | 597 | $9K | |
| 70496 | <1% | 145 | $9K | |
| 73502 | <1% | 658 | $9K | |
| 87340 | <1% | 562 | $9K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 526 | $8K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,035 | $8K |
| 76801 | <1% | 354 | $8K | |
| A9270 | Non-covered item or service | <1% | 3,111 | $8K |
| 73110 | <1% | 572 | $8K | |
| 82570 | <1% | 661 | $8K | |
| 83550 | <1% | 1,105 | $8K | |
| 74183 | <1% | 27 | $7K | |
| 93017 | <1% | 104 | $7K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 301 | $7K |
| 43245 | <1% | 15 | $6K | |
| 99221 | <1% | 555 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,610 | $6K |
| 86901 | <1% | 1,189 | $6K | |
| 96376 | <1% | 3,195 | $6K | |
| 82550 | <1% | 2,591 | $6K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 457 | $5K |
| 80076 | <1% | 630 | $5K | |
| 83970 | <1% | 166 | $5K | |
| 98927 | <1% | 181 | $5K | |
| 96368 | <1% | 154 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,974 | $5K |
| 76857 | <1% | 368 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 284 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,130 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 73 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,945 | $4K |
| 93321 | <1% | 17 | $4K | |
| 84100 | <1% | 1,114 | $4K | |
| 76536 | <1% | 21 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 864 | $4K |
| 84153 | <1% | 232 | $4K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 34 | $4K |
| 83690 | <1% | 5,997 | $4K | |
| 82077 | <1% | 2,487 | $4K | |
| 82043 | <1% | 438 | $3K | |
| 12011 | <1% | 16 | $3K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 13 | $3K |
| 86706 | <1% | 215 | $3K | |
| 98928 | <1% | 96 | $3K | |
| 81025 | <1% | 19,825 | $3K | |
| 82553 | <1% | 1,425 | $3K | |
| 94760 | <1% | 3,389 | $2K | |
| 83605 | <1% | 2,127 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 477 | $2K |
| 73590 | <1% | 223 | $2K | |
| 87077 | <1% | 966 | $2K | |
| 85652 | <1% | 332 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 274 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 52 | $2K |
| 86703 | <1% | 1,997 | $2K | |
| 93356 | <1% | 110 | $2K | |
| 76642 | <1% | 14 | $2K | |
| 85379 | <1% | 1,205 | $2K | |
| 82330 | <1% | 1,656 | $2K | |
| 98926 | <1% | 57 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,940 | $2K |
| 82746 | <1% | 264 | $2K | |
| 87040 | <1% | 614 | $2K | |
| 92610 | <1% | 30 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,154 | $1K |
| 84550 | <1% | 285 | $1K | |
| 85730 | <1% | 1,607 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 506 | $1K |
| 82784 | <1% | 68 | $1K | |
| 86480 | <1% | 16 | $1K | |
| 85018 | <1% | 1,636 | $964.91 | |
| 82248 | <1% | 301 | $949.48 | |
| 80143 | <1% | 304 | $909.52 | |
| 87186 | <1% | 721 | $909.40 | |
| 73140 | <1% | 72 | $852.03 | |
| 84132 | <1% | 1,725 | $829.95 | |
| 92526 | <1% | 22 | $779.62 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,411 | $749.25 |
| 87205 | <1% | 706 | $749.05 | |
| 83615 | <1% | 112 | $740.38 | |
| 97162 | <1% | 13 | $736.90 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,597 | $725.46 |
| 87522 | Neg quan hep c or qual rna | <1% | 16 | $715.05 |
| 82375 | <1% | 1,504 | $691.33 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,550 | $669.08 |
| 00731 | <1% | 751 | $668.64 | |
| 90686 | <1% | 83 | $666.44 | |
| J1815 | Injection, insulin, per 5 units | <1% | 162 | $663.11 |
| 87481 | <1% | 309 | $633.75 | |
| 87070 | <1% | 349 | $631.12 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 421 | $622.40 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 774 | $603.97 |
| 90656 | <1% | 43 | $580.08 | |
| 84156 | <1% | 95 | $562.26 | |
| 83721 | <1% | 70 | $545.00 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 19 | $523.60 |
| 80179 | <1% | 274 | $507.16 | |
| 83050 | <1% | 1,514 | $460.73 | |
| 82435 | <1% | 1,388 | $455.00 | |
| 84403 | <1% | 19 | $450.70 | |
| 73080 | <1% | 41 | $422.47 | |
| 73090 | <1% | 14 | $417.35 | |
| 87808 | <1% | 809 | $413.47 | |
| 86038 | <1% | 25 | $409.69 | |
| Q3014 | Telehealth originating site facility fee | <1% | 14 | $389.58 |
| 80074 | <1% | 17 | $332.75 | |
| 94799 | <1% | 17 | $326.17 | |
| 80320 | <1% | 209 | $297.43 | |
| 82010 | <1% | 388 | $284.77 | |
| 84295 | <1% | 1,470 | $270.16 | |
| 85045 | <1% | 137 | $263.42 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 452 | $259.59 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 584 | $250.57 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 842 | $243.41 |
| 83520 | <1% | 13 | $223.39 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,169 | $213.89 |
| J2704 | Injection, propofol, 10 mg | <1% | 5,523 | $182.01 |
| J3490 | Unclassified drugs | <1% | 40 | $169.09 |
| 83695 | <1% | 57 | $156.04 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,688 | $154.92 |
| 87430 | <1% | 402 | $150.65 | |
| 73552 | <1% | 37 | $135.05 | |
| 84165 | <1% | 13 | $114.76 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 253 | $105.14 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 128 | $103.60 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,639 | $100.51 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 552 | $94.13 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,378 | $91.19 |
| 81003 | <1% | 317 | $84.46 | |
| 84703 | <1% | 78 | $82.46 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,613 | $77.81 |
| 80164 | <1% | 28 | $72.71 | |
| 84155 | <1% | 16 | $68.65 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,740 | $65.07 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 159 | $58.78 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 27 | $58.01 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 905 | $57.28 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 147 | $49.92 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 439 | $48.56 |
| 88342 | <1% | 40 | $48.31 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 295 | $47.44 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,878 | $47.40 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 37 | $44.30 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,961 | $41.62 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 250 | $31.88 |
| 84145 | <1% | 36 | $28.65 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 35 | $25.28 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 950 | $13.92 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 41 | $13.82 |
| 71101 | <1% | 50 | $11.75 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 464 | $11.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 47 | $9.19 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 174 | $6.75 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 66 | $5.16 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 58 | $3.04 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 149 | $2.18 |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | 0% | 30 | $0.00 |
| 00811 | 0% | 262 | $0.00 | |
| 87660 | 0% | 26 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 158 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 24 | $0.00 |
| 3078F | 0% | 146 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 48 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 32 | $0.00 |
| 87899 | 0% | 27 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 27 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 116 | $0.00 |
| 87480 | 0% | 26 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 134 | $0.00 |
| 74174 | 0% | 14 | $0.00 | |
| 3074F | 0% | 181 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 15 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 18 | $0.00 |
| C1769 | Guide wire | 0% | 292 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 20 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 80 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 92 | $0.00 |
| 00813 | 0% | 78 | $0.00 | |
| 3079F | 0% | 41 | $0.00 | |
| 87510 | 0% | 26 | $0.00 | |
| 00952 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.